Drug May Boost Women's Sexual Desire
Study Shows Flibanserin Increases Satisfying Encounters for Women With Low Libido
Second Opinion continued...
Boehringer Ingelheim is continuing studies. Recruitment of both
premenopausal and postmenopausal women with HSDD for new clinical trials is
beginning, Sand says.
He wouldn't comment on a possible timeline of when the drugmaker might ask
for FDA approval or when it may be on the market.